+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Choroidal Neovascularization Market by Treatment Type, Drug Class, Disease Type, Lesion Type, Line Of Therapy, Distribution Channel, End User - Global Forecast to 2030- Product Image
Choroidal Neovascularization Market by Treatment Type, Drug Class, Disease Type, Lesion Type, Line Of Therapy, Distribution Channel, End User - Global Forecast to 2030- Product Image
Sale

Choroidal Neovascularization Market by Treatment Type, Drug Class, Disease Type, Lesion Type, Line Of Therapy, Distribution Channel, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 197 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6014771
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Choroidal Neovascularization Market grew from USD 6.38 billion in 2024 to USD 6.88 billion in 2025. It is expected to continue growing at a CAGR of 7.66%, reaching USD 9.94 billion by 2030.

Setting the Stage for Choroidal Neovascularization Insights

Choroidal neovascularization represents a critical frontier in retinal disease management, characterized by the pathological growth of new blood vessels beneath the retina. This aberrant vascular proliferation precipitates fluid leakage, hemorrhage, and ultimately irreversible vision loss if left unchecked. Often associated with conditions such as neovascular age-related macular degeneration and pathologic myopia, CNV imposes a significant burden on patients and healthcare systems alike. Advances in therapeutic modalities have reshaped expectations, but the evolving treatment landscape demands a comprehensive understanding of clinical efficacy, safety profiles, and market dynamics.

In this executive summary, we delve into the multifaceted dimensions of the global CNV market, offering an authoritative synthesis of current trends, competitive forces, and emerging opportunities. Our analysis bridges clinical insights with commercial imperatives, articulating the strategic significance of evolving therapies, regulatory shifts, and regional nuances. By illuminating key drivers and addressing potential barriers, this report equips decision-makers with the clarity needed to formulate robust strategies. As the prevalence of CNV continues to rise, stakeholders must navigate an increasingly complex environment-our introduction sets the stage for informed, data-driven action.

Emerging Paradigm Shifts Transforming the CNV Treatment Landscape

The CNV treatment landscape is undergoing transformative shifts driven by breakthroughs in molecular science and digitized care pathways. A surge of next-generation anti-VEGF agents, including advancements in fusion proteins and long-acting formulations, underscores the industry’s pivot toward enhanced dosing convenience and sustained efficacy. Concurrently, combination approaches that integrate photodynamic therapy with anti-VEGF agents promise synergistic benefits, particularly in cases with atypical lesion morphology.

Beyond pharmacotherapy, the integration of artificial intelligence-enabled imaging platforms is redefining diagnostic accuracy and therapeutic monitoring. These digital solutions facilitate real-time lesion characterization, enabling personalized dosing regimens and early detection of subclinical relapse. Regulatory bodies have also embraced adaptive trial frameworks, accelerating the approval of novel biologics and gene therapies targeting CNV. This confluence of technological innovation and progressive policy is catalyzing a patient-centric paradigm, wherein precision medicine and data-driven insights converge to optimize clinical outcomes.

Assessing the Impact of US Tariffs on CNV Therapeutics

The introduction of United States tariffs in 2025 has reverberated across the global CNV supply chain, exerting pressure on the importation of biologics and raw materials essential to anti-VEGF production. Manufacturers have responded by reassessing sourcing strategies and seeking alternative suppliers in cost-competitive regions. These realignments have mitigated some cost burdens but have also generated transitional inefficiencies, particularly in logistics and quality assurance.

Pricing negotiations with payers have become more nuanced as stakeholders balance the imperative for affordable therapies against the need to sustain robust research and development pipelines. In certain cases, increased tariff-driven costs have been absorbed by manufacturers to preserve market access, while in others, they have necessitated strategic repricing. Amid these headwinds, partnerships between domestic and international entities have intensified, leveraging shared manufacturing capacities to hedge against tariff volatility. Ultimately, the cumulative effect of these policies underscores the importance of resilient supply networks and agile commercial frameworks to safeguard patient access and corporate profitability.

Unraveling CNV Market Complexity Through Strategic Segmentation

A nuanced segmentation framework reveals the intricate architecture of the CNV market. Treatment modalities span Anti-VEGF Therapy, featuring agents such as Aflibercept, Bevacizumab, Brolucizumab, Conbercept, and Ranibizumab, alongside Combination Therapy that links photodynamic approaches with anti-VEGF regimens, and standalone Photodynamic Therapy anchored by Verteporfin. Each therapeutic avenue addresses distinct clinical presentations and dosing preferences, engendering diverse competitive dynamics.

Dissecting drug classes highlights the dichotomy between fusion proteins and monoclonal antibodies, each offering unique pharmacokinetic and immunogenic profiles. Disease typology further refines market insights, contrasting the epidemiology and treatment challenges of neovascular age-related macular degeneration with those of pathologic myopia. Lesion subtypes-classic, mixed, occult-introduce additional complexity, guiding therapeutic selection and trial design. Line of therapy stratification, from first through third line, illustrates patient pathways and unmet needs at each treatment juncture. Finally, distribution channels, encompassing hospital pharmacies and retail outlets, interact with end-user landscapes in ambulatory surgical centers, hospitals, and specialized ophthalmology clinics, collectively shaping access, reimbursement, and utilization patterns.

Regional Dynamics Shaping CNV Market Trajectories

Regional dynamics exert a profound influence on CNV market evolution, with the Americas leading in innovation adoption and accelerated regulatory approvals. The United States, in particular, maintains a robust infrastructure for clinical trials and reimbursement frameworks that incentivize premium therapies, while Latin American markets present opportunities for expansion amid growing epidemiological awareness and improving diagnostic capacity.

In Europe, Middle East & Africa, heterogeneous healthcare ecosystems drive varied uptake rates. Western European countries benefit from consolidated payer systems and high patient awareness, whereas emerging markets in Eastern Europe and the Gulf Cooperation Council navigate budgetary constraints and divergent regulatory timelines. Pan-regional collaborations are fostering harmonized standards, expediting the introduction of advanced therapies.

Asia-Pacific distinguishes itself through a combination of large patient populations and escalating investments in healthcare infrastructure. Countries such as Japan and South Korea are at the forefront of adopting gene-based interventions and digital monitoring platforms. Simultaneously, expanding hospital networks in China and India are catalyzing market growth, supported by government initiatives aimed at broadening access to sight-saving treatments.

Leading Players Driving Innovation in CNV Care

Industry leaders have intensified efforts to consolidate their market positions through strategic partnerships, acquisitions, and innovative pipeline developments. Established pharmaceutical companies continue to refine their anti-VEGF portfolios, focusing on next-generation molecular entities that promise extended durability and reduced injection frequency. Concurrently, biotech innovators are advancing gene therapy candidates and novel biologics into late-stage clinical trials, challenging incumbents with differentiated mechanisms of action.

Collaborative agreements between device makers and pharmaceutical firms are also on the rise, embedding imaging diagnostics directly into treatment workflows. These alliances aim to create seamless care ecosystems that enhance patient engagement and improve adherence. Moreover, companies are investing in data analytics platforms to capture real-world evidence, supporting value-based reimbursement models and demonstrating long-term cost-effectiveness. As competitive intensity escalates, agility in go-to-market execution and the capacity to navigate complex regulatory landscapes will determine which organizations emerge as dominant forces in the CNV arena.

Strategic Imperatives for Industry Leaders in CNV Space

To navigate the rapidly evolving CNV landscape, industry leaders should prioritize the development of extended-duration therapies that reduce treatment burden while maintaining or enhancing efficacy. Strengthening supply chain resilience through diversified manufacturing partnerships and regional production hubs will mitigate tariff-related disruptions and ensure consistent product availability. Engaging early with payers and health technology assessment bodies can streamline reimbursement pathways, particularly for high-cost biologics and gene-based interventions.

Investing in digital infrastructure, including AI-driven imaging and patient monitoring platforms, will facilitate personalized treatment paradigms and improve long-term outcomes. Forming cross-sector alliances between pharmaceutical, device, and data analytics organizations can create holistic care models that resonate with physicians and patients alike. Finally, deploying targeted outreach in underserved markets-leveraging telemedicine and mobile screening initiatives-will expand access to CNV diagnostics and therapies, driving both clinical and commercial impact.

Rigorous Research Methodology Underpinning the Analysis

This analysis is underpinned by a rigorous, multi-tiered research methodology that combines primary intelligence with comprehensive secondary data. Primary research involved in-depth interviews with a cross-section of stakeholders, including key opinion leaders, payers, and senior executives from pharmaceutical and device manufacturers. These insights were corroborated through a structured questionnaire process, ensuring a balanced representation of clinical and commercial perspectives.

Secondary research encompassed a thorough review of peer-reviewed journals, regulatory filings, clinical trial registries, and industry reports. Data triangulation techniques were applied to reconcile discrepancies and validate market dynamics. Advanced analytical tools facilitated trend extrapolation and competitive benchmarking, while quality control measures were embedded at each stage to maintain the highest standards of accuracy and reliability. This robust approach guarantees that our findings reflect the most current and actionable intelligence available.

Closing Reflections on the CNV Market Outlook

The CNV market is at a pivotal juncture, shaped by scientific breakthroughs, policy developments, and shifting patient expectations. Innovative anti-VEGF formulations and emerging gene-based therapies herald a new era of long-acting treatments, while digital advancements are redefining diagnostic precision and care delivery. Regional variations in regulatory frameworks and healthcare infrastructure present both challenges and opportunities, underscoring the need for agile strategies.

As the industry grapples with tariff-induced supply chain complexities and intensifying competitive pressures, strategic segmentation and targeted investments will be critical. Organizations that successfully integrate clinical innovation with commercial acumen-supported by resilient partnerships and data-driven decision-making-will be best positioned to capture growth. These conclusions provide a roadmap for stakeholders seeking to navigate the evolving CNV ecosystem and deliver meaningful value to patients and investors alike.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Treatment Type
    • Anti-Vegf Therapy
      • Aflibercept
      • Bevacizumab
      • Brolucizumab
      • Conbercept
      • Ranibizumab
    • Combination Therapy
      • Photodynamic + Anti-Vegf
    • Photodynamic Therapy
      • Verteporfin
  • Drug Class
    • Fusion Proteins
    • Monoclonal Antibodies
  • Disease Type
    • Neovascular Amd
    • Pathologic Myopia
  • Lesion Type
    • Classic Cnv
    • Mixed Cnv
    • Occult Cnv
  • Line Of Therapy
    • First Line
    • Second Line
    • Third Line
  • Distribution Channel
    • Hospital Pharmacy
    • Retail Pharmacy
  • End User
    • Ambulatory Surgical Centers
    • Hospitals
    • Ophthalmology Clinics
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Regeneron Pharmaceuticals, Inc.
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Bayer AG
  • Sanwa Kagaku Kenkyusho Co. Ltd.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Choroidal Neovascularization Market, by Treatment Type
8.1. Introduction
8.2. Anti-Vegf Therapy
8.2.1. Aflibercept
8.2.2. Bevacizumab
8.2.3. Brolucizumab
8.2.4. Conbercept
8.2.5. Ranibizumab
8.3. Combination Therapy
8.3.1. Photodynamic + Anti-Vegf
8.4. Photodynamic Therapy
8.4.1. Verteporfin
9. Choroidal Neovascularization Market, by Drug Class
9.1. Introduction
9.2. Fusion Proteins
9.3. Monoclonal Antibodies
10. Choroidal Neovascularization Market, by Disease Type
10.1. Introduction
10.2. Neovascular Amd
10.3. Pathologic Myopia
11. Choroidal Neovascularization Market, by Lesion Type
11.1. Introduction
11.2. Classic Cnv
11.3. Mixed Cnv
11.4. Occult Cnv
12. Choroidal Neovascularization Market, by Line Of Therapy
12.1. Introduction
12.2. First Line
12.3. Second Line
12.4. Third Line
13. Choroidal Neovascularization Market, by Distribution Channel
13.1. Introduction
13.2. Hospital Pharmacy
13.3. Retail Pharmacy
14. Choroidal Neovascularization Market, by End User
14.1. Introduction
14.2. Ambulatory Surgical Centers
14.3. Hospitals
14.4. Ophthalmology Clinics
15. Americas Choroidal Neovascularization Market
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. Argentina
16. Europe, Middle East & Africa Choroidal Neovascularization Market
16.1. Introduction
16.2. United Kingdom
16.3. Germany
16.4. France
16.5. Russia
16.6. Italy
16.7. Spain
16.8. United Arab Emirates
16.9. Saudi Arabia
16.10. South Africa
16.11. Denmark
16.12. Netherlands
16.13. Qatar
16.14. Finland
16.15. Sweden
16.16. Nigeria
16.17. Egypt
16.18. Turkey
16.19. Israel
16.20. Norway
16.21. Poland
16.22. Switzerland
17. Asia-Pacific Choroidal Neovascularization Market
17.1. Introduction
17.2. China
17.3. India
17.4. Japan
17.5. Australia
17.6. South Korea
17.7. Indonesia
17.8. Thailand
17.9. Philippines
17.10. Malaysia
17.11. Singapore
17.12. Vietnam
17.13. Taiwan
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. Regeneron Pharmaceuticals, Inc.
18.3.2. F. Hoffmann-La Roche Ltd
18.3.3. Novartis AG
18.3.4. Bayer AG
18.3.5. Sanwa Kagaku Kenkyusho Co. Ltd.
19. ResearchAI
20. ResearchStatistics
21. ResearchContacts
22. ResearchArticles
23. Appendix
List of Figures
FIGURE 1. CHOROIDAL NEOVASCULARIZATION MARKET MULTI-CURRENCY
FIGURE 2. CHOROIDAL NEOVASCULARIZATION MARKET MULTI-LANGUAGE
FIGURE 3. CHOROIDAL NEOVASCULARIZATION MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 10. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2030 (%)
FIGURE 16. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 18. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 20. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. UNITED STATES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 24. UNITED STATES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ASIA-PACIFIC CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. ASIA-PACIFIC CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. CHOROIDAL NEOVASCULARIZATION MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 30. CHOROIDAL NEOVASCULARIZATION MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. CHOROIDAL NEOVASCULARIZATION MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY AFLIBERCEPT, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY BROLUCIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY CONBERCEPT, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY RANIBIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC + ANTI-VEGF, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY VERTEPORFIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY FUSION PROTEINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY NEOVASCULAR AMD, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PATHOLOGIC MYOPIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY CLASSIC CNV, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY MIXED CNV, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY OCCULT CNV, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY OPHTHALMOLOGY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 63. CANADA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 64. CANADA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2030 (USD MILLION)
TABLE 65. CANADA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 66. CANADA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, 2018-2030 (USD MILLION)
TABLE 67. CANADA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 68. CANADA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 69. CANADA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2018-2030 (USD MILLION)
TABLE 70. CANADA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 71. CANADA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 72. CANADA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 73. MEXICO CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 74. MEXICO CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2030 (USD MILLION)
TABLE 75. MEXICO CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 76. MEXICO CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, 2018-2030 (USD MILLION)
TABLE 77. MEXICO CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 78. MEXICO CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 79. MEXICO CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2018-2030 (USD MILLION)
TABLE 80. MEXICO CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 81. MEXICO CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 82. MEXICO CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 83. BRAZIL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 84. BRAZIL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2030 (USD MILLION)
TABLE 85. BRAZIL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 86. BRAZIL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, 2018-2030 (USD MILLION)
TABLE 87. BRAZIL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 88. BRAZIL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 89. BRAZIL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2018-2030 (USD MILLION)
TABLE 90. BRAZIL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 91. BRAZIL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 94. ARGENTINA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2030 (USD MILLION)
TABLE 95. ARGENTINA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2030 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, 2018-2030 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 108. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2018-2030 (USD MILLION)
TABLE 110. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 114. UNITED KINGDOM CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 115. UNITED KINGDOM CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2030 (USD MILLION)
TABLE 116. UNITED KINGDOM CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 117. UNITED KINGDOM CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, 2018-2030 (USD MILLION)
TABLE 118. UNITED KINGDOM CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 119. UNITED KINGDOM CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 120. UNITED KINGDOM CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2018-2030 (USD MILLION)
TABLE 121. UNITED KINGDOM CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 122. UNITED KINGDOM CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 123. UNITED KINGDOM CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 124. GERMANY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 125. GERMANY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2030 (USD MILLION)
TABLE 126. GERMANY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 127. GERMANY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, 2018-2030 (USD MILLION)
TABLE 128. GERMANY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 129. GERMANY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 130. GERMANY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2018-2030 (USD MILLION)
TABLE 131. GERMANY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 132. GERMANY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 133. GERMANY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 134. FRANCE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 135. FRANCE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2030 (USD MILLION)
TABLE 136. FRANCE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 137. FRANCE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, 2018-2030 (USD MILLION)
TABLE 138. FRANCE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 139. FRANCE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 140. FRANCE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2018-2030 (USD MILLION)
TABLE 141. FRANCE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 142. FRANCE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 143. FRANCE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 144. RUSSIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 145. RUSSIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2030 (USD MILLION)
TABLE 146. RUSSIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 147. RUSSIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, 2018-2030 (USD MILLION)
TABLE 148. RUSSIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 149. RUSSIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 150. RUSSIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2018-2030 (USD MILLION)
TABLE 151. RUSSIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 152. RUSSIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 153. RUSSIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 154. ITALY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 155. ITALY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2030 (USD MILLION)
TABLE 156. ITALY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 157. ITALY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, 2018-2030 (USD MILLION)
TABLE 158. ITALY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 159. ITALY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 160. ITALY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2018-2030 (USD MILLION)
TABLE 161. ITALY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 162. ITALY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 163. ITALY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 164. SPAIN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 165. SPAIN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2030 (USD MILLION)
TABLE 166. SPAIN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 167. SPAIN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, 2018-2030 (USD MILLION)
TABLE 168. SPAIN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 169. SPAIN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 170. SPAIN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2018-2030 (USD MILLION)
TABLE 171. SPAIN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 172. SPAIN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 173. SPAIN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 174. UNITED ARAB EMIRATES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 175. UNITED ARAB EMIRATES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2030 (USD MILLION)
TABLE 176. UNITED ARAB EMIRATES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 177. UNITED ARAB EMIRATES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, 2018-2030 (USD MILLION)
TABLE 178. UNITED ARAB EMIRATES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 179. UNITED ARAB EMIRATES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 180. UNITED ARAB EMIRATES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2018-2030 (USD MILLION)
TABLE 181. UNITED ARAB EMIRATES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 182. UNITED ARAB EMIRATES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 183. UNITED ARAB EMIRATES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 184. SAUDI ARABIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 185. SAUDI ARABIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2030 (USD MILLION)
TABLE 186. SAUDI ARABIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 187. SAUDI ARABIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, 2018-2030 (USD MILLION)
TABLE 188. SAUDI ARABIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 189. SAUDI ARABIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 190. SAUDI ARABIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2018-2030 (USD MILLION)
TABLE 191. SAUDI ARABIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 192. SAUDI ARABIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 193. SAUDI ARABIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 194. SOUTH AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 195. SOUTH AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2030 (USD MILLION)
TABLE 196. SOUTH AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 197. SOUTH AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, 2018-2030 (USD MILLION)
TABLE 198. SOUTH AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 199. SOUTH AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 200. SOUTH AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2018-2030 (USD MILLION)
TABLE 201. SOUTH AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 202. SOUTH AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 203. SOUTH AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 204. DENMARK CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 205. DENMARK CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2030 (USD MILLION)
TABLE 206. DENMARK CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 207. DENMARK CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, 2018-2030 (USD MILLION)
TABLE 208. DENMARK CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 209. DENMARK CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 210. DENMARK CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2018-2030 (USD MILLION)
TABLE 211. DENMARK CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 212. DENMARK CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 213. DENMARK CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 214. NETHERLANDS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 215. NETHERLANDS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2030 (USD MILLION)
TABLE 216. NETHERLANDS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 217. NETHERLANDS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, 2018-2030 (USD MILLION)
TABLE 218. NETHERLANDS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 219. NETHERLANDS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 220. NETHERLANDS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2018-2030 (USD MILLION)
TABLE 221. NETHERLANDS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 222. NETHERLANDS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 223. NETHERLANDS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 224. QATAR CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 225. QATAR CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2030 (USD MILLION)
TABLE 226. QATAR CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 227. QATAR CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, 2018-2030 (USD MILLION)
TABLE 228. QATAR CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 229. QATAR CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 230. QATAR CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2018-2030 (USD MILLION)
TABLE 231. QATAR CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 232. QATAR CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 233. QATAR CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 234. FINLAND CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 235. FINLAND CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2030 (USD MILLION)
TABLE 236. FINLAND CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 237. FINLAND CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, 2018-2030 (USD MILLION)
TABLE 238. FINLAND CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 239. FINLAND CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 240. FINLAND CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2018-2030 (USD MILLION)
TABLE 241. FINLAND CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 242. FINLAND CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 243. FINLAND CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 244. SWEDEN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 245. SWEDEN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2030 (USD MILLION)
TABLE 246. SWEDEN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 247. SWEDEN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, 2018-2030 (USD MILLION)
TABLE 248. SWEDEN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 249. SWEDEN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 250. SWEDEN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2018-2030 (USD MILLION)
TABLE 251. SWEDEN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 252. SWEDEN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 253. SWEDEN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 254. NIGERIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 255. NIGERIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2030 (USD MILLION)
TABLE 256. NIGERIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 257. NIGERIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, 2018-2030 (USD MILLION)
TABLE 258. NIGERIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 259. NIGERIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 260. NIGERIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2018-2030 (USD MILLION)
TABLE 261. NIGERIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 262. NIGERIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 263. NIGERIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 264. EGYPT CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 265. EGYPT CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2030 (USD MILLION)
TABLE 266. EGYPT CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 267. EGYPT CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, 2018-2030 (USD MILLION)
TABLE 268. EGYPT CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 269. EGYPT CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 270. EGYPT CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2018-2030 (USD MILLION)
TABLE 271. EGYPT CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 272. EGYPT CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 273. EGYPT CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 274. TURKEY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 275. TURKEY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2030 (USD MILLION)
TABLE 276. TURKEY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 277. TURKEY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, 2018-2030 (USD MILLION)
TABLE 278. TURKEY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 279. TURKEY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 280. TURKEY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2018-2030 (USD MILLION)
TABLE 281. TURKEY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 282. TURKEY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 283. TURKEY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 284. ISRAEL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 285. ISRAEL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2030 (USD MILLION)
TABLE 286. ISRAEL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 287. ISRAEL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, 2018-2030 (USD MILLION)
TABLE 288. ISRAEL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 289. ISRAEL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 290. ISRAEL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2018-2030 (USD MILLION)
TABLE 291. ISRAEL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 292. ISRAEL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 293. ISRAEL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 294. NORWAY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 295. NORWAY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2030 (USD MILLION)
TABLE 296. NORWAY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 297. NORWAY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, 2018-2030 (USD MILLION)
TABLE 298. NORWAY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 299. NORWAY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 300. NORWAY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2018-2030 (USD MILLION)
TABLE 301. NORWAY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 302. NORWAY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 303. NORWAY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 304. POLAND CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 305. POLAND CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2030 (USD MILLION)
TABLE 306. POLAND CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 307. POLAND CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, 2018-2030 (USD MILLION)
TABLE 308. POLAND CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 309. POLAND CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Choroidal Neovascularization market report include:
  • Regeneron Pharmaceuticals, Inc.
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Bayer AG
  • Sanwa Kagaku Kenkyusho Co. Ltd.

Table Information

Report AttributeDetails
No. of Pages197
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 6.88 Billion
Forecasted Market Value ( USD ) by 2030 $ 9.94 Billion
Compound Annual Growth Rate7.6%
Regions CoveredGlobal
No. of Companies Mentioned6

Related Topics

Related Reports

Choroidal Neovascularization Market Report by Product Type, Treatment Type, Application, and Region 2024-2032 - Product Image

Choroidal Neovascularization Market Report by Product Type, Treatment Type, Application, and Region 2024-2032

  • Report
  • 149 Pages
  • Global
From
Choroidal Neovascularization - Pipeline Insight, 2025 - Product Image

Choroidal Neovascularization - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Ranibizumab (Lucentis) Biosimilars Pipeline Review - Product Image

Ranibizumab (Lucentis) Biosimilars Pipeline Review

  • Report
  • Global
From
Myopic Macular Degeneration (MMD) - Epidemiology Forecast - 2034 - Product Image

Myopic Macular Degeneration (MMD) - Epidemiology Forecast - 2034

  • Report
  • 60 Pages
  • Global
From
Lucentis (Ranibizumab) Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts - Product Image

Lucentis (Ranibizumab) Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

  • Report
  • 175 Pages
  • Global
From

About the Market

Choroidal Neovascularization (CNV) is a condition in which abnormal blood vessels grow beneath the retina in the eye. It is a major cause of vision loss in age-related macular degeneration (AMD). Optical treatments for CNV include laser photocoagulation, photodynamic therapy, and anti-VEGF injections. Laser photocoagulation is used to destroy the abnormal blood vessels and prevent further vision loss. Photodynamic therapy uses a light-activated drug to destroy the abnormal vessels. Anti-VEGF injections are used to block the growth of new vessels and reduce fluid leakage. The CNV market is highly competitive, with a number of companies offering treatments and products. These include Novartis, Regeneron, Allergan, Roche, Bayer, and Santen Pharmaceuticals. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.